Please select the eligibility criteria that correspond to the clinical trial below.
Title: Individual Versus Standard rFSH Dose for Controlled Ovarian Stimulation and Intrauterine Insemination. A Prospective Randomised Multi Centre Study
Brief Summary: The purpose of this study is to test if recombinant follicle stimulating hormone (rFSH) given in individual doses, according to a nomogram we have constructed based on our results from a previous study, results in more patients maturing 2-3 follicles compared to standard dose.


Options:
A: Inclusion Criteria:

* Dispensed one of 12 drugs or classes of drugs where baseline safety laboratory monitoring is recommended and labs have not been completed 6 months prior or 5 days after the dispense of the medication.
* 18 years of age or older
* 12-month HMO membership
* drug benefit coverage
* has telephone number

Exclusion Criteria:

* recommended baseline laboratory monitoring completed
* receives care and/or resides in hospice, nursing home, care outside HMO
* enrolled in other care management program
* nonEnglish speaking needing translation services
B: Inclusion Criteria:

* Age between 25-39 years
* First stimulation with rFSH only
* Indication for intrauterine insemination with standard rFSH starting dose
* Regular menstrual bleeding with a cycle between 21-35 days
* Two ovaries
* Bilateral tuba patency
* Semen analysis must be sufficient for insemination according to the diagnostic analysis.

Exclusion Criteria:

* More than three former stimulated intrauterine insemination cycles
C: Inclusion Criteria:

1. Men and women, ages 18 to 60 years, inclusive. Earliest inclusion day is the 18th birthday and the latest is the day before the 61st birthday.
2. A diagnosis of schizophrenia or schizoaffective disorder according to ICD-10 classification.
3. Increased risk for relapse, defined as having at least 1 psychiatric hospitalization for psychosis within the past 3 years and at least 2 psychiatric hospitalizations for psychosis in total (i.e. ≥ 2 hospitalizations).
4. Clinical Global Impression scale - Severity (CGI-S) ≤ 3 at study Visit 1.
5. All patients must be on stable doses of antipsychotic medication during the study entry.
6. Absence of organic mental disorder, mental disorder due to psychoactive substance use or mental retardation.
7. Presence of a cooperating family member, caregiver or other person who is in frequent contact with the patient (at least 4 times a week) and who is willing to participate in the trial.
8. Signed written informed consent. The informed consent process must be documented by signing the informed consent form prior to any study-related procedures.
9. Eligibility for mobile phone communicating.

Exclusion Criteria:

1. Participation in another relapse prevention program or another interventional clinical trial will be prohibited during the entire participation in the study. Subjects enrolled in observational (non-interventional) trials are not excluded from this study.
2. Hayward compliance rating scale score \< 2 at Visit 1.
D: Inclusion Criteria:

* New participants will be those \>=18 years old who are appropriate candidates for and being initiated on warfarin therapy with target international normalized prothrombin time ratio (INR) range of either 2-3 or 2.5-3.5 and with intent to be treated for at least 1 month and willing to sign informed consent.
* Those with target INR 2.5-3.5 may be enrolled with dose adjustment for this higher target per Gage et-al. (i.e., 11% increase in dose).
* Dose modification also will be made for amiodarone based on prior, published experience (i.e., 22% decrease in dose).

Exclusion Criteria:

* Those not appropriate for warfarin (e.g., pregnancy) or for pharmacogenetic (PG)-guided dosing for any reason,
* Those having received rifampin within 3 weeks,
* Those with severe co-morbidities (e.g., creatinine \> 2.5,hepatic insufficiency, active malignancy, advanced physiological age, noncompliance risk, expected survival \<6 months), and
* Physician or patient preference.

Answer: B